Aps Press Releases
This document was uploaded by user and they confirmed that they have the permission to share it. If you are author or own the copyright of this book, please report to us by using this DMCA report form. Report DMCA
Overview
Download & View Aps Press Releases as PDF for free.
More details
- Words: 1,767
- Pages: 6
Press Release
Applied Protein Sciences and Biomodels Collaborate to Boost Supportive Cancer Care 04.28.09, 7:58 PM ET BusinessWire - Applied Protein Sciences, a biotechnology start-up focused on preventing mucositis, announced today that it has entered into a strategic alliance with Biomodels. This alliance allows speedier product development and helps APS expand its pipeline to develop proprietary drugs for mucositis, proctitis and IBD. APS expects to launch its clinical program later this year. "We are very excited about partnering with Biomodels," said Aman Johar, CEO of APS. "This relationship allows us flexibility to customize our pre-clinical studies, maintain our clinical end-points and effectively utilize capital resources. A full-scale collaboration extends our research platform and provides access to leading scientists and researchers. Biomodels' proven models reliably predict clinical success in an extremely complex field of mucositis. APS products can be the standard of care for preventing mucositis - saving over $2 billion annually in hospitalization costs." "Together Biomodels and APS will finalize oral mucositis studies and also rapidly test a number of mechanistically-related therapeutic areas using appropriate validated models," said Edward Fey, Managing Partner of Biomodels. "This alliance represents a new business model for the outsourcing of pre-clinical services and is designed to fulfill the specific needs of early stage pharmaceutical companies," Fey adds. Mucositis remains an unmet medical need and APS products may become the "standard of care" for solid tumor patients undergoing cancer treatment. Mucositis affects over 400,000 patients annually. In a recent survey, 66% of mucositis patients said that physicians need to be educated more about its treatments. There are currently no approved medications for preventing mucositis. This collaboration boosts APS efforts to build a technology platform that can be scaled to encompass all aspects of supportive oncology care. About Applied Protein Sciences APS is developing proprietary proteins that help with the growth of the mucosal tissue, thereby preventing the onset of mucositis. With APS' products, patients can remain on chemotherapy or radiation for longer, significantly increasing their survival. In addition to mucositis, APS drug platform includes candidates for proctitis and IBD - significant unmet medical needs in supportive oncology care. APS aims to secure orphan drug status and has a broad portfolio of issued US and worldwide patents rights. APS recently released a mechanism of action for its drug candidates. APS is privately owned and investors include Innovation Management Sciences. www.appliedprotein.com About Biomodels Biomodels is a preclinical CRO helping biotechnology companies enter clinical trials phase of the drug development process. Biomodels specializes in screening studies to evaluate efficacy and define mechanism of action to expedite the process. Over the years Biomodels core competencies in oncology and cancer supportive care include a range of inflammatory and mucosal diseases. The net effects are preclinical data that are meaningfully translatable to the clinic and added confidence in the design of clinical studies, all of which conveys substantial cost savings. www.biomodels.com SOURCE: Applied Protein Sciences
Applied Protein Sciences Amanjyot S. Johar, 650-969-8300 [email protected] or Biomodels Edward G. Fey, 857228-1100 [email protected]
Print
Press Release
Back to story
Source: Applied Protein Sciences
Applied Protein Sciences and Biomodels Collaborate to Boost Supportive Cancer Care On Tuesday April 28, 2009, 7:58 pm EDT
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Applied Protein Sciences, a biotechnology start-up focused on preventing mucositis, announced today that it has entered into a strategic alliance with Biomodels. This alliance allows speedier product development and helps APS expand its pipeline to develop proprietary drugs for mucositis, proctitis and IBD. APS expects to launch its clinical program later this year. “We are very excited about partnering with Biomodels,” said Aman Johar, CEO of APS. “This relationship allows us flexibility to customize our pre-clinical studies, maintain our clinical end-points and effectively utilize capital resources. A full-scale collaboration extends our research platform and provides access to leading scientists and researchers. Biomodels’ proven models reliably predict clinical success in an extremely complex field of mucositis. APS products can be the standard of care for preventing mucositis – saving over $2 billion annually in hospitalization costs.” “Together Biomodels and APS will finalize oral mucositis studies and also rapidly test a number of mechanistically-related therapeutic areas using appropriate validated models,” said Edward Fey, Managing Partner of Biomodels. “This alliance represents a new business model for the outsourcing of pre-clinical services and is designed to fulfill the specific needs of early stage pharmaceutical companies,” Fey adds. Mucositis remains an unmet medical need and APS products may become the “standard of care” for solid tumor patients undergoing cancer treatment. Mucositis affects over 400,000 patients annually. In a recent survey, 66% of mucositis patients said that physicians need to be educated more about its treatments. There are currently no approved medications for preventing mucositis. This collaboration boosts APS efforts to build a technology platform that can be scaled to encompass all aspects of supportive oncology care. About Applied Protein Sciences APS is developing proprietary proteins that help with the growth of the mucosal tissue, thereby preventing the onset of mucositis. With APS’ products, patients can remain on chemotherapy or radiation for longer, significantly increasing their survival. In addition to mucositis, APS drug platform includes candidates for proctitis and IBD - significant unmet medical needs in supportive oncology care. APS aims to secure orphan drug status and has a broad portfolio of issued US and worldwide patents rights. APS recently released a mechanism of action for its drug candidates. APS is privately owned and investors include Innovation Management Sciences. www.appliedprotein.com About Biomodels Biomodels is a preclinical CRO helping biotechnology companies enter clinical trials phase of the drug development process. Biomodels specializes in screening studies to evaluate efficacy and define mechanism of action to expedite the process. Over the years Biomodels core competencies in oncology and cancer supportive care include a range of inflammatory and mucosal diseases. The net effects are preclinical data that are meaningfully translatable to the clinic and added confidence in the design of clinical studies, all of which conveys substantial cost savings. www.biomodels.com
Contact: Applied Protein Sciences Amanjyot S. Johar, 650-969-8300 [email protected] or Biomodels Edward G. Fey, 857-228-1100 [email protected]
Copyright © 2008 Business Wire. All rights reserved. All the news releases provided by Business Wire are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials by posting, archiving in a public web site or database, or redistribution in a computer network is strictly forbidden.
Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright Policy - Send Feedback
Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quote data delayed 15 minutes for Nasdaq, NYSE and Amex. Real-Time continuous streaming quotes are available through our premium service. You may turn streaming quotes on or off. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Yahoo! is not an investment adviser and does not provide, endorse or review any information or data contained herein.
Print | Close this window
Applied Protein Sciences and Biomodels Collaborate to Boost Supportive Cancer Care Tue Apr 28, 2009 7:58pm EDT
MOUNTAIN VIEW, Calif.--(Business Wire)-Applied Protein Sciences, a biotechnology start-up focused on preventing mucositis, announced today that it has entered into a strategic alliance with Biomodels. This alliance allows speedier product development and helps APS expand its pipeline to develop proprietary drugs for mucositis, proctitis and IBD. APS expects to launch its clinical program later this year. "We are very excited about partnering with Biomodels," said Aman Johar, CEO of APS."This relationship allows us flexibility to customize our pre-clinical studies, maintain our clinical end-points and effectively utilize capital resources. A full-scale collaboration extends our research platform and provides access to leading scientists and researchers. Biomodels` proven models reliably predict clinical success in an extremely complex field of mucositis. APS products can be the standard of care for preventing mucositis - saving over $2 billion annually in hospitalization costs." "Together Biomodels and APS will finalize oral mucositis studies and also rapidly test a number of mechanistically-related therapeutic areas using appropriate validated models," said Edward Fey, Managing Partner of Biomodels. "This alliance represents a new business model for the outsourcing of pre-clinical services and is designed to fulfill the specific needs of early stage pharmaceutical companies," Fey adds. Mucositis remains an unmet medical need and APS products may become the "standard of care"for solid tumor patients undergoing cancer treatment. Mucositis affects over 400,000 patients annually. In a recent survey, 66% of mucositis patients said that physicians need to be educated more about its treatments. There are currently no approved medications for preventing mucositis. This collaboration boosts APS efforts to build a technology platform that can be scaled to encompass all aspects of supportive oncology care. About Applied Protein Sciences APS is developing proprietary proteins that help with the growth of the mucosal tissue, thereby preventing the onset of mucositis. With APS` products, patients can remain on chemotherapy or radiation for longer, significantly increasing their survival. In addition to mucositis, APS drug platform includes candidates for proctitis and IBD - significant unmet medical needs in supportive oncology care. APS aims to secure orphan drug status and has a broad portfolio of issued US and worldwide patents rights. APS recently released a mechanism of action for its drug candidates. APS is privately owned and investors include Innovation Management Sciences. www.appliedprotein.com About Biomodels Biomodels is a preclinical CRO helping biotechnology companies enter clinical trials phase of the drug development process. Biomodels specializes in screening studies to evaluate efficacy and define mechanism of action to expedite the process. Over the years Biomodels core competencies in oncology and cancer supportive care include a range of inflammatory and mucosal diseases. The net effects are preclinical data that are meaningfully translatable to the clinic and added confidence in the design of clinical studies, all of which conveys substantial cost savings.
www.biomodels.com
Applied Protein Sciences Amanjyot S. Johar, 650-969-8300 [email protected] or Biomodels Edward G. Fey, 857-228-1100 [email protected] Copyright Business Wire 2009 © Thomson Reuters 2009. All rights reserved. Users may download and print extracts of content from this website for their own personal and non-commercial use only. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. Thomson Reuters and its logo are registered trademarks or trademarks of the Thomson Reuters group of companies around the world. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
Applied Protein Sciences and Biomodels Collaborate to Boost Supportive Cancer Care 04.28.09, 7:58 PM ET BusinessWire - Applied Protein Sciences, a biotechnology start-up focused on preventing mucositis, announced today that it has entered into a strategic alliance with Biomodels. This alliance allows speedier product development and helps APS expand its pipeline to develop proprietary drugs for mucositis, proctitis and IBD. APS expects to launch its clinical program later this year. "We are very excited about partnering with Biomodels," said Aman Johar, CEO of APS. "This relationship allows us flexibility to customize our pre-clinical studies, maintain our clinical end-points and effectively utilize capital resources. A full-scale collaboration extends our research platform and provides access to leading scientists and researchers. Biomodels' proven models reliably predict clinical success in an extremely complex field of mucositis. APS products can be the standard of care for preventing mucositis - saving over $2 billion annually in hospitalization costs." "Together Biomodels and APS will finalize oral mucositis studies and also rapidly test a number of mechanistically-related therapeutic areas using appropriate validated models," said Edward Fey, Managing Partner of Biomodels. "This alliance represents a new business model for the outsourcing of pre-clinical services and is designed to fulfill the specific needs of early stage pharmaceutical companies," Fey adds. Mucositis remains an unmet medical need and APS products may become the "standard of care" for solid tumor patients undergoing cancer treatment. Mucositis affects over 400,000 patients annually. In a recent survey, 66% of mucositis patients said that physicians need to be educated more about its treatments. There are currently no approved medications for preventing mucositis. This collaboration boosts APS efforts to build a technology platform that can be scaled to encompass all aspects of supportive oncology care. About Applied Protein Sciences APS is developing proprietary proteins that help with the growth of the mucosal tissue, thereby preventing the onset of mucositis. With APS' products, patients can remain on chemotherapy or radiation for longer, significantly increasing their survival. In addition to mucositis, APS drug platform includes candidates for proctitis and IBD - significant unmet medical needs in supportive oncology care. APS aims to secure orphan drug status and has a broad portfolio of issued US and worldwide patents rights. APS recently released a mechanism of action for its drug candidates. APS is privately owned and investors include Innovation Management Sciences. www.appliedprotein.com About Biomodels Biomodels is a preclinical CRO helping biotechnology companies enter clinical trials phase of the drug development process. Biomodels specializes in screening studies to evaluate efficacy and define mechanism of action to expedite the process. Over the years Biomodels core competencies in oncology and cancer supportive care include a range of inflammatory and mucosal diseases. The net effects are preclinical data that are meaningfully translatable to the clinic and added confidence in the design of clinical studies, all of which conveys substantial cost savings. www.biomodels.com SOURCE: Applied Protein Sciences
Applied Protein Sciences Amanjyot S. Johar, 650-969-8300 [email protected] or Biomodels Edward G. Fey, 857228-1100 [email protected]
Press Release
Back to story
Source: Applied Protein Sciences
Applied Protein Sciences and Biomodels Collaborate to Boost Supportive Cancer Care On Tuesday April 28, 2009, 7:58 pm EDT
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Applied Protein Sciences, a biotechnology start-up focused on preventing mucositis, announced today that it has entered into a strategic alliance with Biomodels. This alliance allows speedier product development and helps APS expand its pipeline to develop proprietary drugs for mucositis, proctitis and IBD. APS expects to launch its clinical program later this year. “We are very excited about partnering with Biomodels,” said Aman Johar, CEO of APS. “This relationship allows us flexibility to customize our pre-clinical studies, maintain our clinical end-points and effectively utilize capital resources. A full-scale collaboration extends our research platform and provides access to leading scientists and researchers. Biomodels’ proven models reliably predict clinical success in an extremely complex field of mucositis. APS products can be the standard of care for preventing mucositis – saving over $2 billion annually in hospitalization costs.” “Together Biomodels and APS will finalize oral mucositis studies and also rapidly test a number of mechanistically-related therapeutic areas using appropriate validated models,” said Edward Fey, Managing Partner of Biomodels. “This alliance represents a new business model for the outsourcing of pre-clinical services and is designed to fulfill the specific needs of early stage pharmaceutical companies,” Fey adds. Mucositis remains an unmet medical need and APS products may become the “standard of care” for solid tumor patients undergoing cancer treatment. Mucositis affects over 400,000 patients annually. In a recent survey, 66% of mucositis patients said that physicians need to be educated more about its treatments. There are currently no approved medications for preventing mucositis. This collaboration boosts APS efforts to build a technology platform that can be scaled to encompass all aspects of supportive oncology care. About Applied Protein Sciences APS is developing proprietary proteins that help with the growth of the mucosal tissue, thereby preventing the onset of mucositis. With APS’ products, patients can remain on chemotherapy or radiation for longer, significantly increasing their survival. In addition to mucositis, APS drug platform includes candidates for proctitis and IBD - significant unmet medical needs in supportive oncology care. APS aims to secure orphan drug status and has a broad portfolio of issued US and worldwide patents rights. APS recently released a mechanism of action for its drug candidates. APS is privately owned and investors include Innovation Management Sciences. www.appliedprotein.com About Biomodels Biomodels is a preclinical CRO helping biotechnology companies enter clinical trials phase of the drug development process. Biomodels specializes in screening studies to evaluate efficacy and define mechanism of action to expedite the process. Over the years Biomodels core competencies in oncology and cancer supportive care include a range of inflammatory and mucosal diseases. The net effects are preclinical data that are meaningfully translatable to the clinic and added confidence in the design of clinical studies, all of which conveys substantial cost savings. www.biomodels.com
Contact: Applied Protein Sciences Amanjyot S. Johar, 650-969-8300 [email protected] or Biomodels Edward G. Fey, 857-228-1100 [email protected]
Copyright © 2008 Business Wire. All rights reserved. All the news releases provided by Business Wire are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials by posting, archiving in a public web site or database, or redistribution in a computer network is strictly forbidden.
Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright Policy - Send Feedback
Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quote data delayed 15 minutes for Nasdaq, NYSE and Amex. Real-Time continuous streaming quotes are available through our premium service. You may turn streaming quotes on or off. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Yahoo! is not an investment adviser and does not provide, endorse or review any information or data contained herein.
Print | Close this window
Applied Protein Sciences and Biomodels Collaborate to Boost Supportive Cancer Care Tue Apr 28, 2009 7:58pm EDT
MOUNTAIN VIEW, Calif.--(Business Wire)-Applied Protein Sciences, a biotechnology start-up focused on preventing mucositis, announced today that it has entered into a strategic alliance with Biomodels. This alliance allows speedier product development and helps APS expand its pipeline to develop proprietary drugs for mucositis, proctitis and IBD. APS expects to launch its clinical program later this year. "We are very excited about partnering with Biomodels," said Aman Johar, CEO of APS."This relationship allows us flexibility to customize our pre-clinical studies, maintain our clinical end-points and effectively utilize capital resources. A full-scale collaboration extends our research platform and provides access to leading scientists and researchers. Biomodels` proven models reliably predict clinical success in an extremely complex field of mucositis. APS products can be the standard of care for preventing mucositis - saving over $2 billion annually in hospitalization costs." "Together Biomodels and APS will finalize oral mucositis studies and also rapidly test a number of mechanistically-related therapeutic areas using appropriate validated models," said Edward Fey, Managing Partner of Biomodels. "This alliance represents a new business model for the outsourcing of pre-clinical services and is designed to fulfill the specific needs of early stage pharmaceutical companies," Fey adds. Mucositis remains an unmet medical need and APS products may become the "standard of care"for solid tumor patients undergoing cancer treatment. Mucositis affects over 400,000 patients annually. In a recent survey, 66% of mucositis patients said that physicians need to be educated more about its treatments. There are currently no approved medications for preventing mucositis. This collaboration boosts APS efforts to build a technology platform that can be scaled to encompass all aspects of supportive oncology care. About Applied Protein Sciences APS is developing proprietary proteins that help with the growth of the mucosal tissue, thereby preventing the onset of mucositis. With APS` products, patients can remain on chemotherapy or radiation for longer, significantly increasing their survival. In addition to mucositis, APS drug platform includes candidates for proctitis and IBD - significant unmet medical needs in supportive oncology care. APS aims to secure orphan drug status and has a broad portfolio of issued US and worldwide patents rights. APS recently released a mechanism of action for its drug candidates. APS is privately owned and investors include Innovation Management Sciences. www.appliedprotein.com About Biomodels Biomodels is a preclinical CRO helping biotechnology companies enter clinical trials phase of the drug development process. Biomodels specializes in screening studies to evaluate efficacy and define mechanism of action to expedite the process. Over the years Biomodels core competencies in oncology and cancer supportive care include a range of inflammatory and mucosal diseases. The net effects are preclinical data that are meaningfully translatable to the clinic and added confidence in the design of clinical studies, all of which conveys substantial cost savings.
www.biomodels.com
Applied Protein Sciences Amanjyot S. Johar, 650-969-8300 [email protected] or Biomodels Edward G. Fey, 857-228-1100 [email protected] Copyright Business Wire 2009 © Thomson Reuters 2009. All rights reserved. Users may download and print extracts of content from this website for their own personal and non-commercial use only. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. Thomson Reuters and its logo are registered trademarks or trademarks of the Thomson Reuters group of companies around the world. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
Related Documents
Aps Press Releases
May 2020 4
Press Releases
May 2020 16
Rcn Press Releases
May 2020 5
A.m. Best Company - Press Releases Press Release
December 2019 5
Aps
December 2019 29